ROCHESTER, Minn., Aug. 10, 2022 (SEND2PRESS NEWSWIRE) — If you’re a comic fanatic, you must agree the artistic illustrations in Manga, are not only enticing but also exciting. This experience is, however, short-lived especially if you can’t read the foreign text in the speech bubbles. The good news is, PDNob Inc. has upgraded its flagship […]
ROCHESTER, Minn., April 6, 2022 (SEND2PRESS NEWSWIRE) — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
ROCHESTER, Minn., Aug. 24, 2021 (SEND2PRESS NEWSWIRE) — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company’s board of directors.
